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Abstract
Objective: To assess the bioavailability of a formulation of metformin 
hydrochloride 850 mg coated tablets as test, compared to a reference 
product with the same dosage form, in healthy volunteers of both 
genders. 
Method: This clinical trial was designed as randomised, comparative, 
single-dose, open-label, two-period, two-sequence, crossover study 
under fasting conditions. 28 healthy volunteers (fourteen men and 
fourteen women) took part in the study. The 850 mg coated tablets 
formulations were administered in a single dose orally. Blood sam-
ples were obtained prior to dosing and at 30 min, 1, 1:20; 1:40, 2, 
2:20, 2:40; 3, 3:20, 3:40 4, 4:30, 5, 6, 8, 12, 16, 24 and 36 hours 
after drug administration with an one week washout period. Plasmatic 
concentrations of metformin were measured by specific and validated 
analytical methods based on high-performance liquid chromatography 
coupled to mass spectrometry (HPLC/MS). The pharmacokinetics pa-
rameter AUC0-36h, AUC0-∞ and Cmax were tested for bioequivalence 
after log transformation of data and ratios of Tmax were evaluated 
non parametrically.
Findings: Data from this study showed that the test and the referen-
ce formulation presented similar results, within the acceptance range 
(80-125%) for AUC0-∞ (area under curve) and Cmax (maximum serum 
concentration of the drug) parameters, satisfying the bioequivalence 
criteria of the Brazilian Health Surveillance Agency and FDA. 
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Introduction
Diabetes is a syndrome defined as a condition of 
heterogeneous metabolic disorder characterized by 
hyperglycemia resulting from defects in insulin se-
cretion and action, or both. This chronic condition 
increases the risk of developing heart disease, cere-
bral stroke and microvascular complications. There 
are frequent demonstrations of blindness, kidney 
failure and peripheral neuropathy. Currently, Type 
2 Diabetes Mellitus (DM2) is a major public health 
diseases globally, having great impact on the eco-
nomy of governments and individuals, as to their 
treatment, in addition to non-pharmacological mea-
sures often becomes necessary the use of medica-
tions [1].
Metformin is the drug of choice for the treatment 
of type 2 diabetes and is the most widely prescri-
bed oral hypoglycemic agent due to its low toxicity 
profile and efficacy. The drug lowers blood glucose 
levels, especially leading to a decrease in hepatic 
gluconeogenesis, which leads to an average decrea-
se in insulin levels, and also promotes glucose up-
take in muscle. Because of their anti-hyperglycemic 
properties and normalization of elevated levels of 
blood glucose, as well as DM2 is also used in poly-
cystic ovary syndrome (PCOS) [2, 3]. 
Because of its widespread use and socio-eco-
nomic difficulties of patients, they often choose 
by the use of generic drugs. Therefore, the refer-
ence drugs and generics have in common the same 
active ingredient, but may differ from each other 
in relation to excipients and pharmaceutical pro-
duction process. The Food and Drug Administra-
tion (FDA) and European Medicines Agency (EMA) 
regulations for generic drug product registration 
regulations require pharmacokinetic data obtained 
by comparative bioavailability trials between the 
formulation reference and test, analyzing the peak 
plasma concentration parameters (Cmax), area under 
the time curve from time 0 to time t (AUC0-t) and 
extrapolated to infinity (AUC0-∞). For the FDA, the 
test product should have a confidence interval (CI) 
of 90% in these three parameters, so that its ap-
plication is met [2, 4].
Bioavailability studies have several functions, such 
as assessing the bioequivalence of drugs, evaluation 
of medicinal products with new active principles, 
evaluation of new formulations, evaluation of phar-
maceutical forms of modified release, evaluation of 
medicinal products with more than one active in-
gredient and assessment of change the regimen of 
a drug [4].
Therefore, we had up to evaluate the bioavail-
ability of a 850mg metformin formulation coated 
tablet (test formulation) versus a 850mg metformin 
tablet formulation coated reference in the national 
market, to analyze the pharmacokinetic parameters 
of metformin formulations tested healthy fasting 
volunteers and inter-individual variability in relation 
to different organic groups, related to the gender.
Methods
Randomised, comparative, open-label, two-period, 
crossover study in which healthy subjets were given 
orally after a 8-hour overnight fast, in each distinct 
Conclusion: These results indicate that the two formulations of 
metformin hydrochloride 850 mg coated tablets are bioequivalent, 
thus, it will be possible to ensure interchangeability between them, 
which can generate market competition and better access to this 
treatment.
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period, a single-dose of the test drug (Metformin 
850mg) or the reference product (Glifage®) pro-
duced by Merck S.A., according to the randomiza-
tion plan.
This study was performed at the Clinical Pharma-
cology Unit (UNIFAC) of the Federal University of 
Ceara and was conducted in accordance with the 
Declaration of Helsinki, and the protocol was appro-
ved by the Ethics Committee of the Federal Univer-
sity of Ceará, in Fortaleza, Brazil, with registration 
number 336.914. All subjects gave their written, 
informed consent and were free to withdraw from 
the trial at any time.
Subjects included in the study were considered 
healthy in the judgment of legally qualified profes-
sionals, based on medical history, physical examina-
tion and the hematological and biochemical labo-
ratory tests prior to their enrollment. After a period 
of screening, 28 healthy volunteers (14 females and 
14 males) who fulfilled the elegibility criteria were 
selected.
Inclusion criteria were: both genders, aged 18 to 
50 years old, body mass index (BMI) between 18.5 
and 28.7 kg/m2, good health conditions with no 
clinically significant diseases, ability to understand 
the nature and purpose of the study, including the 
risks and adverse effects, intention to cooperate 
with the researcher and act in accordance with the 
requirements of the entire clinical trial, which had to 
be confirmed by signing the informed consent form. 
Exclusion criteria were: diseases or health problems, 
addiction habits and pregnancy or breastfeeding.
Volunteers were informed that, with the excep-
tion of oral contraceptives, no other drug could not 
be taken for at least four weeks prior to the study 
and until after its completion. They were also re-
frained from ingesting alcohol, caffeine, chocolate, 
tea or coke containing beverages at least 12 hours 
before each dosing and until collection of the last 
blood sample. 
The subjects received the drug Metformin Hy-
drochloride 850 mg test and reference Metformin 
Hydrochloride 850mg, for oral administration as a 
single dose, between 7:00 and 8:00 am, the day af-
ter confinement in each period. After a minimum of 
eight hours fasting and evaluation of permanence in 
the inclusion and exclusion criteria, subjects received 
one of the formulations under study, having been 
recorded the absolute real-time medication.
Blood samples of 20 ml were collected for indi-
vidual control curves patterns 10 ml for time zero 
through “venous line” heparin introduced in the 
surface of the volunteer’s forearm vein and other 
samples (7 ml) at the following intervals: 30 min, 1, 
1:20; 1:40, 2, 2:20, 2:40; 3, 3:20, 3:40 4, 4:30, 5, 
6, 8, 12, 16, 24 and 36 hours after the medication.
The blood samples were centrifuged at 3000 
rpm for 12 minutes at 8°C. Immediately after cen-
trifugation, plasma was removed (at least 1,0 ml) 
and stored in a suitable vial, also identified at the 
temperature -20°C freezer for storage in a specific 
biological samples located in the unit. The trans-
port of samples to the analytical unit has occurred 
according to standard operating procedure for the 
transport of samples in the current driving period 
of the study.
Plasma concentrations of metformin were quanti-
fied by a specific and validated bioanalytical method 
based on high-performance liquid chromatography 
with detection by mass spectrometry (HPLC-MS), 
and human plasma used as a biological matrix, for 
quantification pharmacokinetics.
Pharmacokinetic parameters were determined 
from the plasma concentration-time data. The 
maximum observed plasma concentration (Cmax)) 
and the time taken to achieve this maximum level 
(Tmax) were obtained directly from the curves.The 
first-order terminal elimination rate constant (Ke) 
was estimated by linear regression from the points 
describing the elimination phase on a log-linear 
plot. The areas under the curve for metformin plas-
ma concentration versus time for 0-36h (AUC0-36h) 
were calculated by applying the linear trapezoidal 
method. The extrapolation of this area to infinity 
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(AUC0-∞) was done by adding the value C36/Ke 
to the calculated AUC0-36 where C36 is the met-
formin plasma concentration at 36h and Ke is the 
first-order terminal elimination rate constant. The 
elimination half-life (t1/2) was derived from this rate 
constant (t1/2 = ln(2)/Ke) where t1/2 is the half-life 
time, ln(2) is the Neperian logarithm and Ke is the 
elimination rate constant. 
Relative bioavailability between the reference 
and test formulations was assessed on the basis 
of maximum plasma concentration of metformin 
(Cmax) and area under the plasma concentration 
versus time curve from time 0 to the last sampling 
time (AUC0-36h) by calculating the mean ratios and 
90% confidence interval (CIs) on log-transformed 
data. The inclusion of the 90% CIs for the ratios 
in the 80% to 125% bioequivalence interval, were 
analyzed using a parametric test (ANOVA). The exis-
tence of residual effect was made based on ANOVA 
sequence tests, using the P value obtained based 
on F_stat of the sequence effect as a parameter 
(Sequence Hypothesis of Model effects). The varia-
bility between the groups (sequence), periods and 
formulations was evaluated using ANOVA test. The 
softwares used to calculate the pharmacokinetic pa-
rameters (Cmax) and AUC) and to carry out statistical 
analysis were WinNonlinTM, version 5.0 (Pharsight, 
Mountain View, CA); and GraphPad Prim, version 
3.02 (Software Inc., San Diego, CA).
Results
The age of the subjects varied between 18 and 39 
years old, with an average of 28.5 years old. In as-
sessing the body mass index there was observed a 
variation of 19,39 to 28,18 kg/m² with an average 
of 23,7kg/m². Seven volunteers had BMI above 25 
are considered overweight, but were included in the 
study because they have reached the limit of 30 kg/
m² BMI. Table 1 presents means and quantitative 
variation of these tests in the selection of volunteers 
(Table 1).
Tables 2 and 3 show the subjects’ pharmacoki-
netic data accordingly to gender, for the test and 
reference formulations (Tables 2 and 3). The maxi-
Table 1.  Laboratory parameters of the study volun-
teers (N=28). Fortaleza, CE, 2015.
Clinical analyte 
reference 
value
Average 
value 
of the 
volunteers
The range 
of variation 
of the 
volunteers
Renal function
Urea 
mg/dL
21-53 25.28 16-49
Uric acid 4.0-8.4 4.93 2.5-6.9
Creatinine 0.6-1.2 0.753 0.55-1.08
Liver function
TGO 
U/L
17-59 22.14 15-34
TGP 21-53 19.14 7-37
Alkaline 
phosphatase
38-126 64.93 39-122
Albumine g/dL 3.5-5.0 4.58 4.1-5.2*
Total bilirubin mg/dL 0.1-1.2 0.73 0.22-2.4*
Metabolic evaluation
Glucose 
mg/dL
70-99 82.4 68-98
Total 
Cholesterol 
less than 239 161.25 117-232
Triglycerides less than 199 82.43 31-177
Blood evaluation
Red cells 
milions/
mL
4.2-6.5 4.75 4-5.2
Hemoglobine g/dL 12-18 13.93 12.1-15.6
Hematocrit (%) 37-54 41.41 37.1-45.6
Leukocytes u/mL 3000-11000 7500 4200-12000*
Canes 
(%)
1-6 1 1-1
Segmented 40-63 54.93 41-78*
Eosinophils 1-6 2.82 01-07*
Basophils 0-3 0.43 0-1
Lymphocytes 20-45 31.93 14-43
Monocytes 2-10 9.25 05-15*
Platelets u/mL 130000-400000 271.000 170000-390000
*: Laboratory changes without clinical significance
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Table 2.  Pharmacokinetic parameters of subjects obtained after the administration of the reference for-
mulation, divided by gender. Fortaleza, CE, 2015.
Cmax 
(ng/mL)
Tmax (h) t(1/2) (h) β (1 /h)
ASC (0- 36h) 
(h*ng/mL)
ASC (0-∞) 
(h*ng/mL)
Male 
Mean 1,208.15 3.61 4.70 0.16 8,454.01 8,537.08
SD 224.43 0.66 1.87 0.05 1,356.06 1,350.49
Minimum 881.12 2.67 3.13 0.07 5,457.39 5521.35
Maximum 1,570.44 5.00 10.13 0.22 10,204.52 10,241.77
CV(%) 18.58 18.26 39.84 28.54 16.04 15.82
Geometric Mean 1,188.64 3.55 4.44 0.16 8,341.43 8,426.30
Female 
Mean 1,341.82 3.69 6.38 0.12 9,876.52 10,004.48
SD 267.79 0.82 2.77 0.04 2,639.74 2,619.22
Minimum 1,046.29 2.33 3.11 0.05 5,419.43 5,830.07
Maximum 1,844.41 5.00 14.00 0.22 14,808.71 14,949.10
CV(%) 19.96 22.12 43.43 35.66 26.73 26.18
Geometric Mean 1,317.94 3.60 5.93 0.12 9,548.31 9,692.09
Table 3.  Pharmacokinetic parameters of subjects obtained after the administration of the test formulation, 
divided by gender. Fortaleza, CE, 2015. Fortaleza, CE, 2015..
Cmax 
(ng/mL)
Tmax (h) t(1/2) (h) β (1/h)
ASC (0- 36h) 
(h*ng/mL)
ASC (0-∞) 
(h*ng/mL)
Male 
Mean 1372.57 3.69 5.61 0.13 9857.54 9968.19
SD 212.13 0.80 1.39 0.03 1995.31 2009.72
Minimum 974.07 2.67 4.13 0.08 6728.08 6823.33
Maximum 1817.70 5.00 8.36 0.17 14751.31 14913.65
CV(%) 15.45 21.60 24.68 22.35 20.24 20.16
Geometric Mean 1357.40 3.61 5.47 0.13 9677.14 9787.24
Female 
Mean 1341.82 3.69 6.38 0.12 9876.52 10004.48
SD 267.79 0.82 2.77 0.04 2639.74 2619.22
Minimum 1046.29 2.33 3.11 0.05 5419.43 5830.07
Maximum 1844.41 5.00 14.00 0.22 14808.71 14949.10
CV(%) 19.96 22.12 43.43 35.66 26.73 26.18
Geometric Mean 1317.94 3.60 5.93 0.12 9548.31 9692.09
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Table 4.  Comparative statistical analysis of pharmacokinetic parameters between the two formulations 
(test and reference). Fortaleza, CE, 2015.
Parameters
Geometric Average ± Standard Deviation
CVintra%
Limits (80-125%)
Power (%)
Reference Test IC (90%)
Cmax (ng/mL) 1251.63± 251.82 1280.25 ± 228.49 9.16 98.11-106.64
99.99ASC(0-36h) (ng*h/mL) 8924.49 ± 2182.91 9162.81 ± 1875.81 9.22 98.45-107.07
ASC(0-∞) (ng*h/mL) 9037.06 ± 2177.04 9260.50 ± 1887.28 8.84 98.43-106.68
Tmax (h) 3.65 ± 0.73 3.58 ± 0.67 - - -
T½ (h) 5.54 ± 2.47 5.56 ± 1.68 - - -
Table 5. Adverse events observed during the study. Fortaleza, CE, 2015.
Subject Adverse Event Intensity Causality Duration Treatment
9 Headache Low Not Related 8 hours Acetaminophen oral, a pill, 750 mg
14 Nausea and vomit Low Related 40 minutes Bromopride, oral, a pill, 10 mg
17 Vomit Low Possible 20 minutes Observation
18
Diarrhea
Low
Possible
1 hour Observation
Headache Remote
19
Diarrhea Low
Possible 20 minutes Observation
Dor abdominal Moderate
20 Nausea and vomit Low Not Related 10 minutes Observation
21 Nausea and vomit Low Possible 40 minutes Bromopride, oral, one pill, 10 mg
22 Headache Low Remote 1 hour Dipyrone, oral, 30 drops, 500 mg/mL
24
Nausea Low Possible 1 hour
Observation Abdominal pain Moderate Possible
15 minutes
Diarrhea Low Possible
26
Abdominal pain Moderate Possible
20 minutes Observation 
Diarrhea Low Possible
27 Nausea Low Possible 1 hour Observation 
28 Headache Low Remote 1 hour Observation
mum concentrations (1274.99 and 1302.16 ng/mL 
for reference and testing respectively) and minimal 
concentrations (13.42 and 12.8 ng/mL) parameters 
were remarkably similar, confirming a similar disso-
lution profile between the formulations and absorp-
tion of drugs.
When analyzing the Cmax, AUC0-36h and AUC0-∞ 
 parameters at Table 4, it is noticeable that the 
variation is within the standard limits (80-125%), 
considering a confidence interval of 90%. It was 
also shown that both formulations had similar geo-
metric means for the same parameters.
Table 5 contains the adverse events observed du-
ring the study, as well as the measures taken for 
its treatment, when needed. The events were all 
of mild or moderate intensity. There were only few 
InternatIonal archIves of MedIcIne 
sectIon: toxIcology & therapeutIcs
ISSN: 1755-7682
2016
Vol. 9 No. 300
doi: 10.3823/2171
© Under License of Creative Commons Attribution 3.0 License 7
situations where the investigator prescribed medica-
tion to treat the event, which was limited to the use 
of antiemetics and analgesics. The reported events 
were mostly gastrointestinal disturbances (nausea, 
vomiting and diarrhea), possibly related to the study 
drug, and headaches, unrelated or remotely related 
to the drug. Only one event (subject 14) was related 
to the study drug by the investigator (Table 5).
Discussion
This study supports strong similarity between test 
and reference formulations in the obtained pharma-
cokinetic parameters, which are within the specified 
limits by the regulatory agency. The AUC0-∞ is an 
important pharmacokinetic parameter that numeri-
cally describes the drug bioavailability, with the aim 
of quantifying the absorbed fraction that reached 
the systemic circulation and becomes available to 
exert its pharmacological effect. In this study are 
found mean values of 9270.78 and 9440.71 hr*ng/
mL for the test and reference formulation respec-
tively.
In a study that investigated the pharmacokinetics 
of metformin hydrochloride tablets 850 mg in six 
nondiabetic volunteers it was found a mean AUC of 
8900 h*ng/mL, similar to the data obtained in this 
study [5]. Another study found a mean of 15620 h*ng/
mL, following the administration of two tablets of 
the reference product of 500 mg in 12 healthy male 
volunteers. This elevated concentration was found 
probably due to the administration of a higher dose 
of 1000 mg [6].
Regarding the Cmax, this study found a mean re-
sult of 1274.99 and 1299.80 ng/mL for the referen-
ce and test formulations respectively, reached at the 
mean times (Tmax) of 3.65 and 3.58 hours after the 
drug administration. The metformin half-lives of the 
two analysed formulations was of 5.54 (reference) 
and 5.56 hours (test). 
Another study found a mean value of 1.7 mg/l 
for Cmax, higher than the two tested formulations 
in this study [5]. Tmax had a mean time of 3 hours, 
which means that concentration peak was reached 
before both of our studied formulations. The half-
life of metformin in this formulation was of 2.7 
hours, a value much lower than those obtained in 
our research. In both studies the formulations were 
administered under fasting conditions.
A similar result was described in another research, 
wherein mean values for Cmax of 1.73 and 1.86 mi-
crog/ml were reported, being achieved at 2.6 and 
2 hours for the test formulation and reference, res-
pectively. It was also observed Cmax values higher 
than in this study, as well as an earlier concentration 
peak. The half-lives of both formulations were lower 
than 3.1 hours [7]. 
After the administration of a 1000mg dose, 
another study reported mean values for Cmax of 
2.385 g/ml reached at the mean time of 2.72 hours 
and an elimination half-life of 2.8 hours [6]. A half 
life of 3.8 hours was found after the administration 
of Metformin hydrochloride 850 mg tablets to 24 
healthy volunteers [8].
Regarding the elevated mean values of the elimi-
nation half-life in our tested formulations, it is inter-
esting to note that it may be beneficial, compared 
with other formulations. Considering that the DM2 
is a chronic and sometimes difficult to control disea-
se, a metformin formulation that enables a greater 
drug residence time in the body can be useful for 
glucose control in diabetic patients.
The absorption of a drug depends on a complex 
series of events until it reaches the systemic circula-
tion and is distributed to its site of action. It starts 
as the pharmaceutical phase, in which the drug is 
released after the disintegration of the pharmaceu-
tical form allowing its dissolution; During the phar-
macokinetics phase, the drug absorption is started 
by passive transport or by the action of transporters, 
is distributed in the body, followed by metabolism 
– majorly hepatic, and degradation in the gastroin-
testinal tract, either by chemical or microbiological 
action; and finally the pharmacodynamic phase in 
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which the drug acts in its molecular target modu-
lating the physiological response [2].
The differences found between the tested formu-
lations and the cited references can be explained 
by several factors, including: different formulations, 
population genetic factors and gender differences. 
In this study, we found significant differences in the 
pharmacokinetic parameters between the genders. 
Female subjects had a mean Cmax) of 1341.82 and 
1372.57 g/mL for the reference and test formula-
tion, respectively, while the male subjects had means 
of 1208.15 and 1144.67. These differences proba-
bly are due to less intense metabolism of women, 
which generates a reduced drug clearance when 
compared to man [9].
Data from the AUC0-∞ parameter corroborates 
this information, showing once again superior phar-
macokinetic mean values in women for test and 
reference formulations (10004.5 e 9938.15 h*ng/
mL) than in men (8537.08 e 8828.17 h*ng/mL). Re-
nal excretion is also a very important factor to be 
considered in differences between genders, since it 
is known that women have a lower renal elimina-
tion rate than men, which can be correlated well 
with expression of dose-dependent adverse events 
[10]. These pharmacokinetic differences between 
genders could be explored, since one of the cli-
nical indications of Metformin is the treatment of 
polycystic ovary syndrome, a female condition with 
constant and prolonged treatment [11].
Regarding the adverse events, seventeen were 
reported during our study, mostly of mild intensity, 
only three moderate. Eleven events were classified 
as having a possible relationship with metformin, 
mainly gastrointestinal reactions. Twelve subjects 
presented at least one event during the study, only 
two of them were male. Four subjects had to be 
medicated for the presented reactions, being pres-
cribed analgesics (paracetamol and dipyrone) and 
antiemetic agents (bromopride).
Literature references describe that the most com-
mon side effects of metformin are gastrointestinal 
reactions, especially nausea, vomiting, abdominal 
discomfort, cramps and indigestion. These effects 
are presented in about 10 to 25% of patients, es-
pecially in early treatment. These effects can be re-
duced if therapy starts with a low dose, gradually 
increasing, and tend to disappear with continued 
treatment [2].
Three subjects had headache complaints that can 
be correlated with abstinence from caffeine and 
other xanthines [12], which are prohibited substan-
ces during the study period, as it could possibly alter 
the pharmacokinetics of the tested formulations, as 
they are metabolism inductors of several drugs [13].
Formulations containing metformin were well to-
lerated, although there was an elevated incidence 
of adverse events in female subjects. The obtained 
data are consistent with the literature. It is described 
that the metabolism and disposition of drugs in wo-
men can occur slowly than in man, due to metabolic 
(hepatic microsomal system) and physiological diffe-
rences (renal clearance rates). Thus, females have 
a higher drug concentration peak that can lead to 
the increased incidence of adverse effects through 
a dose-dependent mechanism [10].
Conclusion
It is concluded that the test formulation is bioequi-
valent to the reference formulation for the pharma-
cokinetic parameters Cmax and AUC0-∞, given the 
statistical analysis and considering a 90% confidence 
interval, meeting the requirements set forth for the 
regulatory agencies ANVISA and FDA (80-125%). 
The comparative bioavailability trials are important 
for the confirmation of the efficacy and safety of 
a new formulation, ensuring the interchangeability 
between them, generating market competition and 
improving the population’s access to medications.
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